Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 58(7): 3737-43, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24752268

RESUMO

In combination with antibiotics, quinine is recommended as the second-line treatment for uncomplicated malaria, an alternative first-line treatment for severe malaria, and for treatment of malaria in the first trimester of pregnancy. Quinine has been shown to have frequent clinical failures, and yet the mechanisms of action and resistance have not been fully elucidated. However, resistance is linked to polymorphisms in multiple genes, including multidrug resistance 1 (Pfmdr1), the chloroquine resistance transporter (Pfcrt), and the sodium/hydrogen exchanger gene (Pfnhe1). Here, we investigated the association between in vitro quinine susceptibility and genetic polymorphisms in Pfmdr1codons 86 and 184, Pfcrt codon 76, and Pfnhe1 ms4760 in 88 field isolates from western Kenya. In vitro activity was assessed based on the drug concentration that inhibited 50% of parasite growth (the IC50), and parasite genetic polymorphisms were determined from DNA sequencing. Data revealed there were significant associations between polymorphism in Pfmdr1-86Y, Pfmdr1-184F, or Pfcrt-76T and quinine susceptibility (P < 0.0001 for all three associations). Eighty-two percent of parasites resistant to quinine carried mutant alleles at these codons (Pfmdr1-86Y, Pfmdr1-184F, and Pfcrt-76T), whereas 74% of parasites susceptible to quinine carried the wild-type allele (Pfmdr1-N86, Pfmdr1-Y184, and Pfcrt-K76, respectively). In addition, quinine IC50 values for parasites with Pfnhe1 ms4760 3 DNNND repeats were significantly higher than for those with 1 or 2 repeats (P = 0.033 and P = 0.0043, respectively). Clinical efficacy studies are now required to confirm the validity of these markers and the importance of parasite genetic background.


Assuntos
Antimaláricos/farmacologia , Resistência a Medicamentos/genética , Genes de Protozoários/genética , Proteínas de Membrana Transportadoras/genética , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Plasmodium falciparum/efeitos dos fármacos , Proteínas de Protozoários/genética , Quinina/farmacologia , Trocadores de Sódio-Hidrogênio/genética , Alelos , Animais , DNA de Protozoário/genética , Genes de Protozoários/fisiologia , Genótipo , Humanos , Quênia , Malária Falciparum/parasitologia , Proteínas de Membrana Transportadoras/fisiologia , Repetições de Microssatélites , Dados de Sequência Molecular , Proteínas Associadas à Resistência a Múltiplos Medicamentos/fisiologia , Testes de Sensibilidade Parasitária , Polimorfismo Genético/genética , Proteínas de Protozoários/fisiologia , Trocadores de Sódio-Hidrogênio/fisiologia
2.
Malar J ; 13: 265, 2014 Jul 09.
Artigo em Inglês | MEDLINE | ID: mdl-25007860

RESUMO

BACKGROUND: The effects that artemether-lumefantrine (AL) has on gametocyte dynamics in the short-term have recently been described. However there is limited long-term longitudinal data on the effect of AL on gametocyte dynamics in asymptomatic children. METHODS: An epidemiological study was conducted in Kombewa, Western Kenya, in which 270 asymptomatic children aged between 12 and 47 months were enrolled. The subjects were randomized to receive either a course of AL or placebo at enrolment. Active follow-up was conducted for one year. RESULTS: The gametocyte prevalence and density dynamics throughout the study period mirrored that of the asexual forms. The proportion of initially parasitaemic subjects becoming gametocytaemic was significantly lower in the AL arm for the first 12 weeks following randomization. The geometric mean gametocyte density was lower in the AL arm for 2 weeks following randomization. None of the variables of interest had a statistically significant effect on the duration of gametocytaemia. There is no effect seen in subjects who are not parasitaemic at the time of drug administration. CONCLUSIONS: The treatment of asymptomatic parasitaemic subjects with AL results in a significant reduction in the proportion of subjects who become gametocytaemic for at least 12 weeks.


Assuntos
Antimaláricos/uso terapêutico , Artemisininas/uso terapêutico , Portador Sadio/tratamento farmacológico , Portador Sadio/epidemiologia , Etanolaminas/uso terapêutico , Fluorenos/uso terapêutico , Malária Falciparum/tratamento farmacológico , Malária Falciparum/epidemiologia , Plasmodium falciparum/isolamento & purificação , Combinação Arteméter e Lumefantrina , Portador Sadio/parasitologia , Pré-Escolar , Estudos de Coortes , Combinação de Medicamentos , Estudos Epidemiológicos , Feminino , Humanos , Lactente , Quênia/epidemiologia , Estudos Longitudinais , Malária Falciparum/parasitologia , Masculino , Parasitemia/diagnóstico , Placebos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA